Skip to main content
Premium Trial:

Request an Annual Quote

Hycor Extends Deadline on Stratagene Acquisition

NEW YORK, Dec. 30 (GenomeWeb News) - Hycor Biomedical yesterday said it had signed an agreement with privately held Stratagene to extend the deadline for closing its proposed merger with the company until Feb. 27, 2004.

All other terms of the merger agreement, announced in July and originally expected to close in the fourth quarter of 2003, remain the same, according to Hycor.

Hycor said that the extension would permit Stratagene to complete work required to restate its financial statements for the year ended Dec. 31, 2002, and to complete a review of its financial statements for the nine months ended Sept. 30, 2003. The restatement of the S-4 form that Stratagene originally filed in October 2003 "primarily involves accounting for currency transactions in a different manner than Stratagene had previously recognized," according to a Hycor statement.

The financial restatement is expected to result in a moderate improvement to Stratagene's previously reported financial results for the year ended Dec. 31, 2002, Hycor said.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.